|
|
|
| Curative Effectiveness of Ginkgo Terpene Lactones Meglumine Injection Combined with Indapamide in Treatment of Hypertension Complicated with Coronary Heart Disease and Its Effects on the Serum MCP-1 H-FABP and SST2 Levels |
| SHI Zhihong, YUE Deyong, GU Lihua, et al |
| Chongming Branch of Xinhua Hospital Affiliated to School of Medicineat Shanghai Jiaotong University, Shanghai 202150, China |
|
|
|
|
Abstract Objective: To study the curative effectiveness of ginkgo terpene lactones meglumine injection combined with indapamide in treatment of hypertension coronary heart disease and its effects on the serum monocyte chemoat-tractant protein-1(MCP-1), Heart fatty-acid-binding protein(H-FABP) and soluble ST2(sST2) levels.Methods: 85 patients of hypertension complicated with coronary heart disease who received therapy from February 2016 to February 2018 in our hospital were selected as research objects, and with the simple random number table, the patients were divided into the observation group (n=43) and the control group (n=42).On the basis of routine treatment, the control group was treated with indapamide.On the basis of the control group, the observation group was given ginkgo terpene lactones meglumine injection for a continuous treatment of 2 courses.The effect of antihypertensive and angina pectoris and the changes of TCM syndrome score, serum MCP-1, H-FABP and sST2 and adverse reaction were compared between the two groups.Results: There was no significant difference between the two groups in the hypotensive effect (P＞0.05); the total effective rate of angina pectoris in the observation group was significantly higher than that of the control group[90.70%(39/43)vs73.81%(31/42)](P＜0.05); after treatment, chest pain, shortness of breath, palpitation syndrome score, serum MCP-1, H-FABP and sst2 were significantly lower than before treatment, the difference in the observation group was significantly greater than that in the control group(P＜0.05);during treatment, the total incidence of adverse reactions in the two groups was 9.30% (4/43) and 7.14% (3/42) respectively, and the difference was not statistically significant(P＞0.05).Conclusion: Ginkgo terpene lactones meglumine injection combined with indapamide is well for hypertension combined with coronary heart disease, which can effectively reduce the expression of serum MCP-1, H-FABP and sST2 levels, improve cardiac function, relieve clinical symptoms, and has high safety, it's worthy of application and promotion.
|
|
|
|
|
|
[1] Nair J, Kakkar VV, Shanker J. Comparative analysis of inflammatory gene expression levels in metabolic syndrome & coronary artery disease[J]. Indian Med Res, 2017, 145(6): 777~785.
[2] Jeong JH, Seo YH, Ahn JY, et al. The prognostic value of serum levels of heart-type fatty acid binding protein and high sensitivity C-reactive protein in patients with increased levels of amino-terminal pro-B type natriuretic peptide[J]. Ann Lab Med, 2016, 36(5): 420~426.
[3] Tkachyeva ON, Kotovskaya YV, Dudinskaya EN. Indapamide SR/amlodipine fixed dose combination: novel approach to effective control of systolic arterial pressure[J]. Kardiologiia, 2017, 57(11): 76~83.
[4] 葛均波,徐永健.内科学[M].北京:人民卫生出版社,2013.236~255.
[5] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.15~17.
[6] Fallatah R, Elasfar A, Amoudi O, et al. Endovascular repair of severe aortic coarctation, transcatheter aortic valve replacement for severe aortic stenosis, and percutaneous coronary intervention in an elderly patient with long term follow-up[J].Saudi Heart Assoc, 2018, 30(3): 271~275.
[7] Glezer On Behalf Of The Forsage Program Participants MG. Adherence of patients to antihypertensive therapy with combination of perindopril and indapamide according to data of the FORSAGE program[J]. Kardiologiia, 2017, 57(4): 33~37.
[8] 朱德建,吕紫梦.冠心病的病因病机及辨证分型[J].中医药信息,2019,36(2):95~99.
[9] Gregg LP, Tio MC, Li X, et al. Association of monocyte chemoattractant protein-1 with death and atherosclerotic events in chronic kidney disease[J]. Am Nephrol, 2018, 47(6): 395~405.
[10] Das UN. Heart-type fatty acid-binding protein (H-FABP) and coronary heart disease[J]. Indian Heart, 2016, 68(1):16~18. |
|
|
|
2020, Vol. 26 
